Lunafem

Quick links to important sections

Lunafem

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lunafem

Lunafem is a foundational medication defined by its dual-hormone composition and its function as a primary method of fertility control. It is a prescription-only synthetic preparation taken orally.

Property Description
Active Ingredients Ethinyl Estradiol and Gestodene
Form Coated Tablet
Pharmacological Class Combined Oral Contraceptive (COC)
Common Use Pregnancy Prevention / Birth Control
Origin Synthetic Hormonal Analogues

What Type of Medicine is Lunafem? (Identity and Classification)

Lunafem is classified as a Combined Oral Contraceptive (COC), which is a synthetic hormonal medication used for effective pregnancy prevention. This prescription-only pharmaceutical preparation is administered orally in the form of a coated tablet. It is clinically recognized as a first-line, reversible method of contraception, with its mechanism of action supported by extensive pharmacological studies. Its identity as a combination product, containing two distinct active ingredients, is central to its therapeutic function and ensures a comprehensive approach to birth control.

Composition: Lunafem’s Dual Active Ingredients (Composition and Origin)

Lunafem is a combination product featuring the two distinct active pharmaceutical ingredients (APIs): Ethinyl Estradiol and Gestodene. Both components are synthetic analogues of the body's natural sex hormones, estrogen and progesterone, allowing for precise control over consistency and potency. Ethinyl Estradiol serves as the estrogen component, while Gestodene provides the progestogenic activity. Gestodene is often categorized as a specific type of third-generation progestogen, which provides unique pharmacological characteristics compared to formulations relying on older progestogen groups. The APIs are combined with solid pharmaceutical excipients within the tablet for consistent systemic delivery.

How Lunafem Works to Prevent Conception (High-Level Mechanism Principle)

The general purpose of Lunafem is to achieve highly dependable contraception by implementing a recognized triple-action physiological mechanism. The combination of synthetic hormones primarily works by effectively suppressing ovulation, thereby inhibiting the monthly release of an egg from the ovaries. This primary action is supported by two secondary effects: the thickening of the cervical mucus to impede sperm mobility, and the alteration of the uterine lining. These three principles of function operate concurrently, a methodology strongly supported by clinical evidence for providing reliable fertility control.

What side effects are possible with Lunafem?

Possible Side Effects and Safety Information

The safety profile of Lunafem, a combined oral contraceptive (COC), is officially categorized based on frequency and the physiological systems affected, as outlined in regulatory documents such as the Summary of Product Characteristics (SmPC) and FDA Prescribing Information.

Adverse reactions are classified from Very Common (occurring in at least 1 in 10 individuals) to Rare (occurring in less than 1 in 1,000 individuals).

Frequency-Classified Adverse Reactions

The most frequently documented side effects, often classified as Very Common, include headache, nausea, and spotting or breakthrough bleeding, particularly during the initial cycles of use. Common reactions often involve mood changes, abdominal pain, breast tenderness, and fluctuations in body weight.

Serious Adverse Reactions and Safety Constraints

Official regulatory labeling identifies the risk of Serious Adverse Reactions (SARs), notably Venous Thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, and Arterial Thromboembolism (ATE), such as stroke and myocardial infarction. The risk of VTE is officially documented as highest during the first year of use or upon re-initiating treatment after a break of four or more weeks.

The medication is subject to strict safety-related restrictions. It is formally contraindicated in individuals with a history of thrombotic disorders, severe liver disease, or certain estrogen-dependent cancers. Furthermore, close safety monitoring is specified for users with underlying conditions like well-controlled hypertension or diabetes, due to potential cardiovascular risks documented in official labeling. This structured approach to safety ensures that risks are clearly communicated and categorized according to the affected System-Organ-Classes, such as Vascular, Nervous System, and Reproductive disorders.

Overdose and Emergency Response

The official regulatory profile for Lunafem, a Combined Oral Contraceptive, indicates that acute ingestion of doses exceeding the usual amount is consistently associated with low acute toxicity. Documentation from government health agencies states that overdose is generally not likely to be life-threatening in adult women.

Documented Manifestations and Classification The most commonly documented clinical manifestations listed in prescribing information are non-severe, focusing on nausea and vomiting. Other signs officially noted include breast tenderness, headache, emotional changes, and unexpected vaginal bleeding. Slight vaginal bleeding is a specific manifestation noted for young girls (pre-menarcheal patients) who have ingested an overdose. The regulatory summaries confirm that no specific antidote is known for Lunafem overdose.

Mandatory Emergency Action Users must seek medical help right away upon suspicion of overdose. Official guidance mandates that individuals contact a Poison Control center immediately for professional assessment and monitoring. Due to the lack of a specific antidote, the only procedural management described in official documents is symptomatic and supportive treatment. This mandated action is required to ensure professional monitoring and appropriate management of all documented symptoms.

Therapeutic Uses of Lunafem

What Lunafem Treats: Main Uses and Benefits

Lunafem is commonly used to provide a supportive, long-term approach to fertility control for women of reproductive age. It is considered relevant as a reversible method of birth control. While combined oral contraceptives (COCs) are commonly used to support pregnancy prevention, they are also applied across domains where additional symptomatic support is needed for various gynecological conditions.


Management of Menstrual Distress

This medication is applied in clinical settings that involve symptoms related to heightened physiological activity of the menstrual cycle, including severe menstrual pain (dysmenorrhea) and excessively heavy menstrual bleeding (menorrhagia). In situations involving symptoms related to systemic imbalance, the medication provides support that helps ease the overall symptom load during symptomatic periods and contributes to improved comfort during periods of heightened discomfort.

Quick Fact: Used for managing Severe Menstrual Pain and Heavy Bleeding symptoms.


Cycle Regularity and Hormonal Symptom Relief

Lunafem is commonly used to help with managing symptoms related to cycle predictability and regularity in cases of persistent or disruptive irregularity. It is also relevant for easing certain hormone-driven manifestations, including moderate hormonal acne and key symptoms associated with conditions like Polycystic Ovary Syndrome (PCOS) and symptomatic relief for Endometriosis. This therapeutic use supports general well-being during symptomatic phases and helps patients cope more steadily with symptom fluctuations.

“Lunafem is applied across domains where additional symptomatic support is needed, primarily for cycle-related distress and hormonal skin symptoms.”

This supports managing symptom clusters that may become intense or disruptive, such as severe menstrual pain and cycle irregularity.

Regulatory References

  1. National Institutes of Health (NIH)

Eligibility and Restrictions for Use

Lunafem (levonorgestrel and ethinyl estradiol tablets) is a combined hormonal contraceptive and is subject to strict eligibility rules documented in official government regulatory labeling. The eligibility profile is defined by conditions that make use absolutely contraindicated due to serious health risks.

Populations for Whom Use is Prohibited (Contraindicated)

  • Thrombotic Risk: Females with a high risk of arterial or venous thrombotic diseases, including a history of Deep Vein Thrombosis, Pulmonary Embolism, Coronary Artery Disease, Cerebrovascular Disease, or inherited/acquired hypercoagulopathies.
  • Age and Smoking: Females over age 35 who smoke.
  • Cancer: Those with current or history of breast cancer or other cancers known to be estrogen- or progestin-sensitive.
  • Hepatic Disease: Females with liver tumors, acute viral hepatitis, or decompensated cirrhosis.
  • Vascular/Metabolic Conditions: Females with uncontrolled hypertension, diabetes with vascular damage, or diabetes of long duration (e.g., >20 years).
  • Pregnancy: Use is contraindicated during known pregnancy.

Other Eligibility Restrictions

  • Post-Surgical/Immobilization: Must be stopped at least four weeks before and through two weeks after major surgery or during prolonged immobilization.
  • Postpartum: Should not be started earlier than four weeks after delivery in females who are not breastfeeding. It is not indicated for use in elderly women or prior to menarche.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Lunafem

Interaction scope Details
Medicinal product categories with documented interactions Hepatic enzyme inducers (e.g., certain anticonvulsants, antibiotics, herbal products), Hepatic enzyme inhibitors, Bile Acid Sequestrants, and certain Antivirals (Hepatitis C regimens).
Specific interacting medicines (if explicitly listed) Carbamazepine, Phenytoin, Rifampicin, Griseofulvin, St. John’s Wort, Ketoconazole, Tizanidine, Ciclosporin (Cyclosporine), Lamotrigine, Colesevelam, and specific anti-Hepatitis C regimens (e.g., Ombitasvir/Paritaprevir/Ritonavir combinations).
Mechanistic basis of interactions (only if stated in label) Modulation of cytochrome P450 enzymes (CYP3A4 induction/inhibition) altering systemic hormone exposure; altered clearance of co-administered drugs (e.g., CYP1A2 inhibition); and binding in the gastrointestinal tract.
Timing-based interaction rules (if applicable) Administration of Lunafem must be separated by at least 4 hours prior to or 4 hours after the administration of a Bile Acid Sequestrant (e.g., Colesevelam) to prevent documented reductions in exposure.
Population-specific interaction notes (if applicable) Interaction risks are officially documented to be amplified in patients with impaired liver function due to the hormones' dependence on hepatic clearance.
Interaction-related restrictions Specific anti-Hepatitis C regimens (e.g., Ombitasvir/Paritaprevir/Ritonavir combinations) are formally contraindicated for co-administration due to the documented risk of elevated liver enzymes (ALT).

Interaction Classifications (High-Level)

Classification Detail
Interaction severity classification (as defined in official documents) Includes Contraindicated Combinations, interactions that officially reduce efficacy (enzyme inducers), and interactions that increase toxicity of co-administered drugs.
Regulatory basis Consistent with information presented in the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC).
Interaction-context constraints (as defined in official documents) Efficacy-reducing interactions are contingent on the degree of enzyme modulation; specific drugs are required to be avoided or necessitate timing adjustments.

Resulting interaction structure

Regulatory documents define the product's interaction structure primarily around pharmacokinetic alterations, emphasizing both the risk of reduced efficacy when co-administered with enzyme inducers and the risk of altered exposure for co-administered drugs due to Lunafem's role as a metabolic modulator. The profile also strictly enumerates a small category of contraindicated combinations due to organ-specific toxicity risks.

Mechanism of Action

The action of Lunafem relies on the synergistic activity of the synthetic progestogen, Gestodene, and the synthetic estrogen, Ethinyl Estradiol, to achieve a triple-action physiological mechanism.Central Suppression of the Endocrine CycleThe hormones act as agonists at Progesterone and Estrogen Receptors in the hypothalamus and pituitary gland. This action imposes a continuous, high-level negative feedback signal on the Hypothalamic-Pituitary-Ovarian (HPO) Axis, suppressing the mid-cycle surge of LH and FSH. This central signaling suppression directly leads to the primary physiological effect of anovulation, preventing the release of an egg from the ovary. Peripheral Barrier and Tissue ModificationGestodene exerts a direct agonistic effect on Progesterone Receptors in peripheral tissues, specifically the cervix and endometrium. This peripheral action rapidly alters the quality and structure of the cervical mucus, creating a thick, tenacious physical barrier that restricts sperm movement. Simultaneously, it induces structural changes in the endometrium, rendering the uterine lining unreceptive to implantation. Dual-Component Mechanistic SynergyEthinyl Estradiol acts to potentiate the central inhibitory effect of Gestodene, increasing the degree and stability of the HPO axis suppression required for anovulation. This synergistic modulation of the endocrine system contributes to the robust physiological interruption of the reproductive process.

Dosage and Administration Information

Administration of Lunafem

Lunafem is a Combined Oral Contraceptive (COC) used according to a standardized, cyclic dosing schedule. The medicine is administered solely via the oral route as a fixed-dose coated tablet.

The standard regimen requires taking one tablet once daily at the same approximate time each day to maintain consistent systemic levels of Ethinyl Estradiol and Gestodene. It may be ingested with or without food, using a small amount of liquid to assist with swallowing. The tablet must be swallowed whole and not crushed.


The Cyclic Dosing Pattern

The regimen follows a structured cyclic pattern, typically comprising 21 days of active tablets followed by 7 days of either inactive (placebo) tablets or a tablet-free interval, completing a 28-day cycle. The sequence of administration must strictly follow the order indicated on the blister packaging to ensure correct cyclical hormone delivery. The overall administration of Lunafem is defined as a long-term use pattern determined by the necessity for fertility control.


Procedural and Time-Specific Instructions

The initiation of the regimen is procedural: tablets are typically started on Day 1 or Day 5 of the menstrual cycle. For non-lactating women, administration is often initiated within 21 to 28 days following delivery or second-trimester abortion.

Crucially, all regulatory labels include a formal Missed Dose Protocol to address interruptions in the daily schedule. If a tablet is missed by less than 12 hours, the tablet is taken immediately. If more than 12 hours have passed, specific steps are required depending on the week of the cycle, as protection may be diminished. These protocols outline the official, non-advisory steps necessary to address any break in the programmed daily use.

Recent Clinical Evidence

Research evidence / Overview of Studies for Lunafem (Ethinyl Estradiol/Gestodene)

This section summarizes the structure of the official research and study types that characterize Lunafem, aligning with regulatory expectations and scientific consensus on Combined Oral Contraceptives (COCs).


Evidence for Use in Pregnancy Prevention (Fertility Control)

Research exploring the contraceptive role of this medication relies on short-term Randomized Controlled Trials (RCTs) and vast observational cohort studies. These studies monitored the occurrence of pregnancy, primarily using the Pearl Index (pregnancies per 100 women-years). The findings derived from these large-scale studies describe the patterns of pregnancy rates observed when the medication was used consistently. Evidence contributes to the broader landscape regarding this class of medication for fertility control.

Evidence for Use in Menstrual Cycle Management

This formulation was studied for its role in conditions involving periods of heightened symptoms, such as severe menstrual pain (dysmenorrhea) and excessively heavy menstrual bleeding (menorrhagia). The research consists primarily of RCTs and systematic reviews. Researchers monitored changes in patient-reported outcomes describing perceived discomfort and objective measures like tracking menstrual blood loss volume. Studies reported that COC use was associated with changes in pain measurements and descriptions of observed changes in menstrual blood loss. Follow-up durations were typically limited to 3 to 6 consecutive cycles for symptom assessment.


Evidence for Use in Hormone-Driven Symptomatic Relief

This medication was evaluated in research exploring outcomes related to systemic imbalance, such as moderate hormonal acne and symptoms associated with Polycystic Ovary Syndrome (PCOS). Studies observed responses over defined time intervals, tracking changes in acne lesion counts and related biochemical markers like androgen biomarkers and SHBG. Research indicates that use was associated with an increase in SHBG levels and changes in certain androgen markers.

What is Still Uncertain or Limited in the Research

One key limitation is that most reported outcomes for symptomatic patterns (e.g., pain, acne) stem from studies with modest sample sizes and limited follow-up durations. This means that there is limited information for long-term outcomes for these non-contraceptive uses. Additionally, while this specific formulation was studied in trials, comparative evidence is lacking in large-scale head-to-head trials against all other low-androgen third-generation progestogens across all indications. The evidence quality varies across studies, and findings were sometimes mixed when comparing highly similar COC formulations.

Key Studies & References

  1. Combined Hormonal Contraception: Efficacy, Safety, and Patient Selection (NIH/StatPearls)

Frequently Asked Questions (FAQ)

Common questions about Lunafem (FAQ)


Q: How quickly do people usually start to notice the intended effects of Lunafem?

According to the official product information, contraceptive efficacy is generally described as beginning after the first seven consecutive days of consistent active tablet use. Regulatory labeling indicates that the use of a non-hormonal back-up method is often necessary during the initial days of the first cycle.

Q: How long does Lunafem stay in the body after the last use?

Regulatory pharmacokinetic studies examine how the active components are processed and cleared from the body. Official data indicates that the components are eliminated with specific half-lives; for instance, Gestodene has a half-life of approximately 18 to 25 hours.

Q: Is it necessary to use Lunafem long-term for the treatment to be effective?

The use of Lunafem for fertility control is officially described as a long-term use pattern. For non-contraceptive benefits, official studies indicate that observed effects were monitored over multiple continuous cycles, typically ranging from three to six cycles.

Q: Does Lunafem affect mood or energy levels according to patient reports?

Official documentation indicates that mood changes are documented as a common adverse reaction. Adverse reactions such as fatigue are sometimes reported, but they are generally not classified in the official documents as very common.

Q: What happens if I miss a dose of Lunafem, according to official guidelines?

Official regulatory documents include a detailed missed dose protocol. The specific steps depend on the time passed since the dose was missed and the week of the cycle. If 12 hours or more have passed, the official protocol states that the use of a non-hormonal back-up method is required for seven days.

Q: Are there known concerns about using Lunafem with common supplements like multivitamins or herbal teas?

Regulatory documents specifically warn about interactions with certain herbal products that induce hepatic enzymes (liver enzymes), such as St. John’s Wort, which may reduce the medicine's effectiveness. Official labeling primarily focuses on specific substances that modulate enzyme activity; general supplements like multivitamins are not enumerated as interacting agents.

Q: Is Lunafem safe for people over the age of 65, based on research?

Official prescribing information states that Lunafem is not indicated for use in elderly women. Regulatory documents confirm there are no clinical studies examining its use in females aged 65 and over.

Q: Can Lunafem be taken if a person has pre-existing kidney issues?

Official labeling details extensive contraindications for severe liver disease, but kidney issues are not listed as a primary contraindication. Specific warnings may exist for patients with severe renal impairment due to potential fluid retention or changes in how the hormones are cleared by the body.

Q: Does Lunafem have known interactions with common anti-depressant medications?

Lunafem is officially described as having the potential to modulate the metabolism of certain co-administered drugs. Official interaction documents focus on drugs that interact via CYP enzyme pathways, and common modern anti-depressants are generally not enumerated in this listing.

Q: What is the risk profile of serious, but rare, side effects reported for Lunafem?

Official safety documents detail that serious adverse reactions (SARs), though officially rare, include Venous Thromboembolism (VTE) and Arterial Thromboembolism (ATE). Other rare events are listed within the official full safety profile and categorized by the affected body systems.

Q: What are the reported success rates of Lunafem in key clinical trials?

The efficacy is summarized in clinical studies using a statistical measure called the Pearl Index, which describes the number of pregnancies per 100 women-years of use. The effectiveness observed in trials is determined using the Pearl Index when the medicine is used consistently and correctly.

Q: If I stop using Lunafem, will the original symptoms return immediately?

Official pharmacological information confirms that the effects of the hormones on the endocrine system and the menstrual cycle are reversible upon discontinuation. This cessation allows the natural suppression of ovulation to wear off, resulting in the return of normal menstrual cycles and fertility.

Q: What kind of specialist typically prescribes Lunafem?

Lunafem is classified as a prescription-only medicine. It is typically prescribed by a healthcare provider, such as a primary care physician or a specialist in women's health (for example, a gynecologist), following a full medical history and assessment.

Q: Does Lunafem contain any common allergens like gluten or lactose?

The official list of ingredients includes both the active and inactive components (excipients). Regulatory documents indicate that tablets containing Gestodene/Ethinyl Estradiol often contain lactose monohydrate as an excipient.

Q: Does Lunafem have any warnings regarding use with alcohol?

Official regulatory documents for this class of medicine do not typically list alcohol as a direct drug interaction that alters the hormonal concentration or efficacy of Lunafem.

Q: Can men use Lunafem for any approved condition, or is it only for women?

Official regulatory prescribing information indicates that Lunafem is solely intended for use in females of reproductive potential for pregnancy prevention and other approved female-specific conditions. Its use is not authorized or indicated for men.

Q: What is the safety classification of Lunafem during pregnancy?

Lunafem is officially classified as contraindicated during known pregnancy. According to historical regulatory categorization, this class of drugs was generally classified as Pregnancy Category X.

Q: Are there different forms of Lunafem available, such as tablet versus liquid?

According to official regulatory information, Lunafem is supplied only as a coated tablet intended for oral administration. No other forms, such as liquid or injectable solutions, are officially available.

Q: Does Lunafem require any special monitoring or blood tests while being used?

Regulatory documents advise that patients should undergo routine monitoring, such as an annual physical examination that includes blood pressure measurements. Specific blood tests may be recommended by a healthcare provider for patients with underlying risk factors.

Q: Is Lunafem a controlled substance or does it have the potential for misuse?

Official regulatory classification lists confirm that Lunafem is not listed as a controlled substance. Furthermore, it is not officially cited in regulatory documents as having a potential for misuse or dependence.

Q: What are the specific lifestyle changes that are recommended while using Lunafem?

Official labeling strongly contraindicates the use of this medicine in females over the age of 35 who smoke. Official documents describe that for eligible users, cessation of smoking is a critical factor due to contraindication constraints.

Q: Are there specific genetic factors that might change how Lunafem works for someone?

Eligibility restrictions officially prohibit use in individuals with inherited risk factors for thrombosis, such as certain known inherited hypercoagulopathies (conditions that cause blood to clot too easily). These genetic factors can affect a person's eligibility.

Q: Are there any long-term studies available that discuss the effects of using Lunafem for several years?

Official documents rely on large-scale observational cohort studies that monitor the long-term effects of Combined Oral Contraceptives (COCs). This research helps track safety risks, particularly concerning venous thromboembolism (VTE), over several years of use.

Q: Why might a patient feel worse before they start feeling better on Lunafem?

Official labeling documents confirm that common side effects, such as nausea and headache, are often observed during the initial cycles of use. The occurrence of these known adverse reactions may contribute to temporary feelings of discomfort as the body adjusts to the medicine.

Q: What is the source of the active ingredient in Lunafem?

Official regulatory documents define both active ingredients, Ethinyl Estradiol and Gestodene, as synthetic analogues of the body's natural sex hormones. This means the components are chemically manufactured rather than derived directly from a natural source.

Q: What kind of monitoring is typically done by healthcare providers when a patient is on Lunafem?

Healthcare providers are officially advised to monitor patients by performing an annual physical examination. This typically includes checks for changes in blood pressure and ensuring that a current medical history is maintained.

How should Lunafem be stored and disposed of?

How to Store and Dispose of Lunafem?

The official storage and disposal guidelines for Lunafem are strictly defined to maintain the stability of the hormonal components (Ethinyl Estradiol and Gestodene) and ensure public safety.

Storage & Disposal Scope Official Requirement
Temperature Requirements Store below 30 C (86 F), generally at Controlled Room Temperature (20 to 25 C).
Environmental Protection Keep in the original blister pack and outer carton to protect the tablets from light and moisture. Do not freeze.
Child-Protection Rule Must be stored out of the sight and reach of children.
Disposal Requirement Dispose of expired or unused medication through an official drug take-back program. If unavailable, mix the tablets with an undesirable substance (e.g., coffee grounds), seal the mixture, and place it in the household trash. Do not flush down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lunafem found in:

A-Z Index: